

# No adverse pregnancy outcomes for Tdap at 32 weeks

14 May 2015



**More information:** [Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

(HealthDay)—Tetanus, diphtheria, and acellular pertussis (Tdap) vaccination at 32 weeks of gestation is not associated with adverse pregnancy or neonatal outcomes, according to a study published online May 6 in *Obstetrics & Gynecology*.

Jamie L. Morgan, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues conducted a retrospective study at a single institution to compare pregnancy outcomes for those who accepted or declined Tdap at 32 weeks of gestation. Overall, 97 percent of 7,378 women who were offered Tdap vaccination accepted.

The researchers observed no differences in stillbirth, major malformations, chorioamnionitis, 5-minute Apgar score, or cord blood pH for those who accepted or declined Tdap. Similar results were also seen for neonatal complications, including ventilation requirement, sepsis, intraventricular hemorrhage, and neonatal death. The unvaccinated cohort had significant increases in preterm birth rates at 36 weeks of gestation or less (12 versus 6 percent; P

"No adverse pregnancy outcomes were identified in association with antepartum Tdap vaccination," the authors write.

APA citation: No adverse pregnancy outcomes for Tdap at 32 weeks (2015, May 14) retrieved 25 January 2022 from <https://medicalxpress.com/news/2015-05-adverse-pregnancy-outcomes-tdap-weeks.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*